Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 15/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.49 |
| ▸ | SRC | P12931 | 10/20 | 0.49 |
| ▸ | SYK | P43405 | 10/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935949 | 0.93 | GSK3A (0.49) | GSK3AMAPK14SRCSYKBRAF | |
| SCHEMBL1936356 | 0.91 | MAPK14 (0.51) | GSK3AMAPK14SRCSYKBRAF | |
| SCHEMBL4089773 | 0.88 | GSK3A (0.48) | GSK3AMAPK14SRCSYKBRAF | |
| SCHEMBL1936368 | 0.85 | MAPK14 (0.55) | GSK3AMAPK14SRCSYKBRAF | |
| SCHEMBL1936472 | 0.84 | GSK3A (0.52) | GSK3AMAPK14SRCSYKBRAF | |
| SCHEMBL4084225 | 0.83 | MAPK14 (0.49) | GSK3AMAPK14SRCSYKBRAF | |
| SCHEMBL1936773 | 0.83 | BRAF (0.51) | GSK3AMAPK14SRCSYKBRAF | |
| SCHEMBL1936288 | 0.83 | GSK3A (0.54) | GSK3AMAPK14SRCSYKBRAF | |
| SCHEMBL2671092 | 0.83 | MAPK14 (0.53) | GSK3AMAPK14SRCSYKBRAF | |
| SCHEMBL1934475 | 0.83 | BRAF (0.56) | GSK3AMAPK14SRCSYKBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8735579-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| EP-2331506-B1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120108572-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| EP-2331506-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010026095-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | HRH2, HRH1, HRH4 | GSK3A 1638/4885MAPK14 2338/4885SRC 3998/4885 |
| US-20120108572-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | HRH2, HRH1, HRH4 | GSK3A 1638/4885MAPK14 2338/4885SRC 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.